Literature DB >> 18806609

Effects of angiotensin-1 converting enzyme inhibition on oxidative stress and bradykinin receptor expression during doxorubicin-induced cardiomyopathy in rats.

Carole Richard1, Benjamin Lauzier, Stéphanie Delemasure, Sébastien Talbot, Stéliana Ghibu, Bertrand Collin, Jacques Sénécal, Franck Menetrier, Catherine Vergely, Réjean Couture, Luc Rochette.   

Abstract

To evaluate the mechanisms and the impact of the angiotensin-converting enzyme inhibitor perindopril (P) in a model of doxorubicin (D)-induced cardiotoxicity, male Wistar rats received D (1 mg/kg/d, IP for 10 days), P (2 mg/kg/d by gavage from day 1 to day 18), D (for 10 days) + P (for 18 days) or saline. D decreased systolic blood pressure and body and heart weights. Left ventricular diastolic diameter was increased by D (P < 0.01), but it was not attenuated by P. D decreased plasma vitamin C (P < 0.05) and increased the ascorbyl radical/vitamin C ratio (P < 0.01). This ratio was attenuated by P. No difference was found among groups in cardiac troponin I, brain natriuretic peptide concentrations, and tissue oxidative stress (OS). Myocardial MCP-1 expression was higher in the D group. Cardiac kinin receptor (B1R and B2R) expression was not affected by D, yet binding sites for B2R and B1R were increased in D+P and P groups, respectively (P < 0.05). In conclusion, D induced cardiac functional alterations, inflammation and plasma OS whereas tissue OS, and cardiac kinin receptors expression were not modified. P did not improve cardiac performance, but it modulated kinin receptor expression and enhanced antioxidant defense.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18806609     DOI: 10.1097/FJC.0b013e3181865f28

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  6 in total

1.  Pretreatment with angiotensin-converting enzyme inhibitor improves doxorubicin-induced cardiomyopathy via preservation of mitochondrial function.

Authors:  Asimina Hiona; Andrew Stephen Lee; Jayan Nagendran; Xiaoyan Xie; Andrew J Connolly; Robert C Robbins; Joseph C Wu
Journal:  J Thorac Cardiovasc Surg       Date:  2010-11-20       Impact factor: 5.209

Review 2.  In Vivo Murine Models of Cardiotoxicity Due to Anticancer Drugs: Challenges and Opportunities for Clinical Translation.

Authors:  Serena L'Abbate; Michela Chianca; Iacopo Fabiani; Annamaria Del Franco; Alberto Giannoni; Giuseppe Vergaro; Chrysanthos Grigoratos; Claudia Kusmic; Claudio Passino; Yuri D'Alessandra; Silvia Burchielli; Michele Emdin; Daniela Maria Cardinale
Journal:  J Cardiovasc Transl Res       Date:  2022-03-21       Impact factor: 4.132

3.  Angiotensin-converting enzyme 2 overexpression protects against doxorubicin-induced cardiomyopathy by multiple mechanisms in rats.

Authors:  Hui Ma; Jing Kong; Yu-Lin Wang; Jun-Long Li; Nai-Hao Hei; Xin-Ran Cao; Jing-Jing Yang; Wen-Jiang Yan; Wen-Jing Liang; Hong-Yan Dai; Bo Dong
Journal:  Oncotarget       Date:  2017-04-11

4.  Cardioprotective effect of metformin against doxorubicin cardiotoxicity in rats.

Authors:  Mustafa Argun; Kazım Üzüm; Mehmet Fatih Sönmez; Abdullah Özyurt; Karabulut Derya; Kübra Tuğçe Çilenk; Sunay Unalmış; Özge Pamukcu; Ali Baykan; Figen Narin; Ferhan Elmalı; Nazmi Narin
Journal:  Anatol J Cardiol       Date:  2015-04-30       Impact factor: 1.596

Review 5.  Anthracycline-induced cardiotoxicity and renin-angiotensin-aldosterone system-from molecular mechanisms to therapeutic applications.

Authors:  Paweł Sobczuk; Magdalena Czerwińska; Marcin Kleibert; Agnieszka Cudnoch-Jędrzejewska
Journal:  Heart Fail Rev       Date:  2022-01       Impact factor: 4.214

6.  LCZ696 ameliorates doxorubicin-induced cardiomyocyte toxicity in rats.

Authors:  Toru Miyoshi; Kazufumi Nakamura; Naofumi Amioka; Omer F Hatipoglu; Tomoko Yonezawa; Yukihiro Saito; Masashi Yoshida; Satoshi Akagi; Hiroshi Ito
Journal:  Sci Rep       Date:  2022-03-23       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.